TGen, Flagship Partner to Hasten Drug Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – TGen Drug Development and Flagship Biosciences today announced a partnership to use their technologies to hasten new drug development.

The deal combines TGen's molecular analysis tools with Flagship's expertise in high-throughput immunohistochemistry to support preclinical drug development and human clinical trials.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.